Should I stay or should I go? There are no easy answers when it comes to timing a job move, says Tim Ewbank, but you can make yourself a more attractive candidate for that next job.(more)
A sea of paperwork or business as usual? Steven Gray looks ahead to the soon-to-be finalised 2008 ABPI Code of Practice and how it will affect everyday practice in the UK industry(more)
Schering-Plough sacrifices begin with Hassan's bonus Schering-Plough's new chief executive and chairman Fred Hassan, has forgone a bonus of up to $2 million bonus to demonstrate his commitment to cost-cutting at the struggling company...(more)
PR's image problem prompts agency name change The pharmaceutical industry's negative view of PR has persuaded healthcare agency Jo Spink Public Relations to re-brand itself as Spink Consumer Relations...(more)
Doctors ask for one more performance indicator An increasing disengagement of GPs from their primary care trusts is threatening to thwart the government's plans for an NHS led by frontline clinicians...(more)
Aventis sues generic rivals over Lovenox Aventis has gone to court in the US to prevent generic versions of its second-biggest drug, blockbuster anti-thrombotic treatment Lovenox, coming to market...(more)
Troubled UK biotechs to merge Cash strapped UK biotech company Xenova is to buy rivals KS Biomedix to create a merged oncology-focused business...(more)
AstraZeneca prepares Crestor for battle AstraZeneca's US salesforce is gearing up to launch its potential blockbuster cholesterol-reducing drug Crestor, after receiving a long-awaited FDA approval...(more)
Genzyme buys SangStat for $600m US biotech company Genzyme is to buy SangStat, a California-based company whose lead product Thymoglobulin is a $77 million-a-year treatment for liver transplant rejection...(more)
Shire cuts back ahead of US expansion Shire Pharmaceuticals is to revert to its original business model of marketing and developing specialist drugs in late stage clinical development...(more)
Merck expands into US proteomics Merck KGaA has bought ProtoPlex, a US-based biotech company specialising in functional genomics and proteomics...(more)
Zyprexa approved for bipolar disorder Eli Lilly's market-leading schizophrenia drug Zyprexa has been granted European approval for the long-term treatment of bipolar disorder...(more)
New GSK joint venture malaria drug approved A new and inexpensive malaria treatment developed by GlaxoSmithKline in collaboration with the World Health Organisation has been approved in the UK...(more)
AstraZeneca accused of blocking Losec competition AstraZeneca faces a major anti-competition investigation after the European Commission accused the company of obstructing competition to its blockbuster ulcer drug Losec...(more)
